ABCL

#2044
AbCellera Biologics Inc. Common Shares
3.61
+3.74%
Sector:
Básica:
Profit Currency:
Rango diario
3.61
3.61
Rango anual
1.89
6.52
Cambio diario
+3.74%
Monthly Change
-10.86%
6 month change
-18.51%
Cambio anual
+32.72%
Cierres anteriores
3.48
Open
3.61
Bid
Ask
Low
3.61
High
3.61
Volumen
47
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.08 B
  • Employee 596
  • Founded 2012
  • CEO Carl Hansen
  • Website www.abcellera.com
  • Headquarter British Columbia, Canada
  • FIGI BBG00LLW2MF2
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-6.98
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

AbCellera Biologics Inc

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Noticias